Literature DB >> 1678563

Glucagonomas of transgenic mice express a wide range of general neuroendocrine markers and bioactive peptides.

G Rindi1, S Efrat, M A Ghatei, S R Bloom, E Solcia, J M Polak.   

Abstract

Pancreatic tumours of transgenic mice carrying a glucagon-promoted simian virus 40 (SV40) T antigen oncogene have been analysed by histological, histochemical, ultrastructural and radioimmunological means. Seven transgenic mice were examined revealing dysplastic and neoplastic lesions in the endocrine pancreas. Four tumours were identified, one of which metastasized to periadrenal spaces and paravertebral lymph nodes. Benign tumours were composed of argyrophilic, endocrine cells reactive to a range of antibodies against neuroendocrine markers (neuron-specific enolase, protein gene product 9.5, chromogranin A, synaptophysin and protein 7B2) and different fragments of the proglucagon molecule (glucagon, glicentin, glucagon-like polypeptides 1 and 2). A few tumour cells expressed pancreatic polypeptide, somatostatin or insulin. Conventional ultrastructural analysis and immunogold labelling revealed typical glucagon-immunoreactive alpha granules which co-stored glicentin and glucagon-like polypeptides 1 and 2. The malignant primary tumour and its metastases were composed mainly of cells which did not show immunoreactivity for neuroendocrine markers or peptides. Atypical, glucagon-immunogold labelled granules were detected at electron microscopy in differentiated tumour cells and C-type retroviral particles in the largest tumour population of degranulated cells. The transgene-encoded oncoprotein SV40 large T-antigen was detected in the nuclei of well-differentiated tumour cells and in alpha cells of some dysplastic islets. All tumour-bearing mice showed high levels of circulating glucagon-like immunoreactivity. Transgenic mice harbouring the glucagon-promoted SV40 T antigen oncogene may provide a model for human glucagonoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678563     DOI: 10.1007/bf01600225

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  50 in total

1.  Mice transgenic for a vasopressin-SV40 hybrid oncogene develop tumors of the endocrine pancreas and the anterior pituitary. A possible model for human multiple endocrine neoplasia type 1.

Authors:  D Murphy; A Bishop; G Rindi; M N Murphy; G W Stamp; J Hanson; J M Polak; B Hogan
Journal:  Am J Pathol       Date:  1987-12       Impact factor: 4.307

Review 2.  Dissecting multistep tumorigenesis in transgenic mice.

Authors:  D Hanahan
Journal:  Annu Rev Genet       Date:  1988       Impact factor: 16.830

3.  Ultrastructural localization of intracellular antigens by the use of protein A-gold complex.

Authors:  J Roth; M Bendayan; L Orci
Journal:  J Histochem Cytochem       Date:  1978-12       Impact factor: 2.479

4.  The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes.

Authors:  L A Sternberger; P H Hardy; J J Cuculis; H G Meyer
Journal:  J Histochem Cytochem       Date:  1970-05       Impact factor: 2.479

Review 5.  Markers for neuroendocrine differentiation.

Authors:  A E Bishop; R F Power; J M Polak
Journal:  Pathol Res Pract       Date:  1988-04       Impact factor: 3.250

Review 6.  Macro- and micro-domains in the endocrine pancreas.

Authors:  L Orci
Journal:  Diabetes       Date:  1982-06       Impact factor: 9.461

7.  Glucagon and glicentin immunoreactivity are topologically segregated in the alpha granule of the human pancreatic A cell.

Authors:  M Ravazzola; L Orci
Journal:  Nature       Date:  1980-03-06       Impact factor: 49.962

8.  Proglucagon processing similar to normal islets in pancreatic alpha-like cell line derived from transgenic mouse tumor.

Authors:  A C Powers; S Efrat; S Mojsov; D Spector; J F Habener; D Hanahan
Journal:  Diabetes       Date:  1990-04       Impact factor: 9.461

9.  Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry.

Authors:  I M Varndell; A E Bishop; K L Sikri; L O Uttenthal; S R Bloom; J M Polak
Journal:  J Histochem Cytochem       Date:  1985-10       Impact factor: 2.479

Review 10.  Pancreatic endocrine tumors.

Authors:  G Klöppel; P U Heitz
Journal:  Pathol Res Pract       Date:  1988-04       Impact factor: 3.250

View more
  8 in total

Review 1.  Classification and functions of enteroendocrine cells of the lower gastrointestinal tract.

Authors:  Ashok R Gunawardene; Bernard M Corfe; Carolyn A Staton
Journal:  Int J Exp Pathol       Date:  2011-04-25       Impact factor: 1.925

Review 2.  The endocrine pancreas and its tumors.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  1993-09       Impact factor: 3.943

3.  25 Years of neuroendocrine neoplasms of the gastrointestinal tract.

Authors:  G Rindi; G Petrone; F Inzani
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

4.  Conditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma.

Authors:  S T Glenn; C A Jones; S Sexton; C M LeVea; S M Caraker; G Hajduczok; K W Gross
Journal:  Oncogene       Date:  2013-12-02       Impact factor: 9.867

5.  Development of colonic and pancreatic endocrine tumours in mice expressing a glucagon-SV40 T antigen transgene.

Authors:  S L Asa; Y C Lee; D J Drucker
Journal:  Virchows Arch       Date:  1996-03       Impact factor: 4.064

Review 6.  Prognostic factors in gastrointestinal endocrine tumors.

Authors:  Guido Rindi; Tiziana D'Adda; Elisabetta Froio; Giovanni Fellegara; Cesare Bordi
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

7.  Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice.

Authors:  Run Yu; Deepti Dhall; Nicholas N Nissen; Cuiqi Zhou; Song-Guang Ren
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

Review 8.  Modelling Pancreatic Neuroendocrine Cancer: From Bench Side to Clinic.

Authors:  Alexander Ney; Gabriele Canciani; J Justin Hsuan; Stephen P Pereira
Journal:  Cancers (Basel)       Date:  2020-10-28       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.